Tricida (TCDA) Tops Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Tricida Announces Third Quarter 2018 Financial Results
November 8, 2018 4:05 PM ESTAdvanced Key Initiatives for NDA Submission
Launched Non-Branded Metabolic Acidosis Disease Awareness Campaign
Presented TRCA-301 Pivotal Trial Results at ASN Kidney Week Late-Breaker Session
Webcast Today at 5:00 pm ET
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida,Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and nine months... More
